- Home
- WEA vs BDTX Comparison
WEA vs BDTX Comparison
Compare WEA & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- BDTX
- Stock Information
- Founded
- WEA 2002
- BDTX 2014
- Country
- WEA United States
- BDTX United States
- Employees
- WEA N/A
- BDTX N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WEA Finance
- BDTX Health Care
- Exchange
- WEA Nasdaq
- BDTX Nasdaq
- Market Cap
- WEA 130.9M
- BDTX 144.9M
- IPO Year
- WEA N/A
- BDTX 2020
- Fundamental
- Price
- WEA $10.77
- BDTX $2.22
- Analyst Decision
- WEA
- BDTX Strong Buy
- Analyst Count
- WEA 0
- BDTX 4
- Target Price
- WEA N/A
- BDTX $15.50
- AVG Volume (30 Days)
- WEA 46.1K
- BDTX 500.7K
- Earning Date
- WEA 01-01-0001
- BDTX 11-05-2024
- Dividend Yield
- WEA 7.87%
- BDTX N/A
- EPS Growth
- WEA N/A
- BDTX N/A
- EPS
- WEA N/A
- BDTX N/A
- Revenue
- WEA N/A
- BDTX N/A
- Revenue This Year
- WEA N/A
- BDTX N/A
- Revenue Next Year
- WEA N/A
- BDTX N/A
- P/E Ratio
- WEA N/A
- BDTX N/A
- Revenue Growth
- WEA N/A
- BDTX N/A
- 52 Week Low
- WEA $9.60
- BDTX $2.09
- 52 Week High
- WEA $11.29
- BDTX $7.66
- Technical
- Relative Strength Index (RSI)
- WEA 36.14
- BDTX 34.45
- Support Level
- WEA $11.00
- BDTX $2.34
- Resistance Level
- WEA $11.01
- BDTX $2.66
- Average True Range (ATR)
- WEA 0.14
- BDTX 0.18
- MACD
- WEA -0.03
- BDTX 0.01
- Stochastic Oscillator
- WEA 19.59
- BDTX 22.85
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.